Eurotransplant International Foundation, Leiden, The Netherlands.
J Heart Lung Transplant. 2011 Jan;30(1):22-8. doi: 10.1016/j.healun.2010.08.006. Epub 2010 Sep 20.
The purpose of the study was to investigate the impact of the lung allocation score (LAS) on mortality among highly urgent (HU) and urgent (U) lung transplant (LTx) candidates in Eurotransplant (ET) and to identify useful additional parameters (LASplus).
All adult LTx candidates for whom a first request for HU or U status was made in 2008 in ET were included (N = 317). Patients were followed until LTx, death on the waiting list (WL), delisting, or closure date (i.e., January 10, 2010). The relationship between the LAS/LASplus and waiting list, post-transplant, and overall mortality was assessed with a multivariate regression model. The LAS and LASplus were decomposed into their basic waitlist and post-transplant components.
Waiting list mortality rate was 22% and 1-year post-transplant mortality rate was 34%. The waitlist component of the LASplus was significantly associated with waiting list mortality (hazard ratio [HR] 1.91, p = 0.021), whereas the LAS was not (p = 0.063). The post-transplant components of both scores were significantly associated with 1-year post-transplant mortality (LAS: HR 2.69, p = 0.005; LASplus: HR 2.55, p = 0.004). Both scores strongly predicted overall mortality (LAS: HR 1.65, p = 0.008; LASplus: HR 1.72, p = 0.005).
LAS accurately predicts overall mortality in critically ill transplant candidates and should therefore be considered as the basis for a new lung allocation policy in ET. An adjustment of the original LAS may be indicated to accurately predict waiting list mortality.
本研究旨在探讨肺分配评分(LAS)对 Eurotransplant(ET)中高度紧急(HU)和紧急(U)肺移植(LTx)候选者死亡率的影响,并确定有用的附加参数(LASplus)。
纳入 2008 年 ET 中首次申请 HU 或 U 状态的所有成人 LTx 候选者(N=317)。患者随访至 LTx、等待名单(WL)上死亡、取消名单或截止日期(即 2010 年 1 月 10 日)。使用多变量回归模型评估 LAS/LASplus 与等待名单、移植后和总体死亡率之间的关系。将 LAS 和 LASplus 分解为基本等待名单和移植后组成部分。
等待名单死亡率为 22%,1 年移植后死亡率为 34%。LASplus 的等待名单组成部分与等待名单死亡率显著相关(危险比 [HR] 1.91,p=0.021),而 LAS 则没有(p=0.063)。两个评分的移植后组成部分均与 1 年移植后死亡率显著相关(LAS:HR 2.69,p=0.005;LASplus:HR 2.55,p=0.004)。两个评分均强烈预测总体死亡率(LAS:HR 1.65,p=0.008;LASplus:HR 1.72,p=0.005)。
LAS 准确预测重症移植候选者的总体死亡率,因此应考虑将其作为 ET 中新型肺分配政策的基础。可能需要对原始 LAS 进行调整以准确预测等待名单死亡率。